Biotek-snakken — Januar 2026
-
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA
(pembrolizumab) in Recurrent Ovarian Cancer: -
Cessatech: Ventis Pharma holder/har afholdt (?) statusmøde med Staq Pharma her primo januar. Ventis Pharma's hjemmeside er nede på 3.-4. døgn nu (ny, opdateret side på vej?) + denne lille analyse giver et fint indblik om Cessatech og kursmuligheder (skrevet af en investor vel og mærke, så lidt bias)
-
Europæiske life science-aktier tager teten efter afvist sparemanøvre fra Trump https://proinvestor.com/investornyt/1400080/europaeiske-life-science-aktier-tager-teten-efter-afvist-sparemanovre-fra-trump
-
Cessatech; hov; fik ikke linket med til analysen: https://stokvalue.substack.com/p/the-one-stock-im-buying-for-my-kids?utm_campaign=post-expanded-share&utm_medium=web&triedRedirect=true
-
Hør Pila Pharmas præsentation fra Investor Konferencen den 26. november https://proinvestor.com/investornyt/1400112/hor-pila-pharmas-praesentation-fra-investor-konferencen-den-26-november
-
$ZYME, Zani combo med tislelizumab (PD-1) + chemotherapy slår trastuzumab + chemo. mOS 26.4 vs 19.2 months og bliver ny 1L SoC. Market reaktion udeblev i først omgang da Zani+Chemo også var forventet at slå Tras+Chemo, Median OS 24.4 vs 19.2 months HR 0.80 p = 0.0564 lige akkurat ikke stat sig. i denne OS interim, men har en OS trend som ved næste iterim OS mid-2026 børe blive stat sig.
-
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to purchase
Yahoo Finance (finance.yahoo.com)
Cessatech og Curasight trykker stadig godt på:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind